摘要 |
<p>The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an topoisomerase inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the topoisomerase inhibitor is irinotecan, or a pharmaceutically acceptable salt thereof, and the disorder is colorectal cancer involving a tumor comprising b-Raf having the V600E mutation.</p> |
申请人 |
F.HOFFMANN-LA ROCHE AG |
发明人 |
DHINGRA, KAPIL;HIGGINS, BRIAN;KOLINSKY, KENNETH;LEE, RICHARD J.;LESTINI, BRIAN;PACKMAN, KATHRYN E.;SU, FEI |